Med-Gemini scores 91% on MedQA. OpenAI's o1-preview hits 96%. Neither number tells you what happens when the algorithm meets ...

TRUTAKNA meets all endpoints in Phase 3 IgA Nephropathy Trial final analysis, confirming eGFR stabilization and disease ...

The Lancet calls out "hard to reach" as a stigmatizing label. For clinical ops, it's a site selection failure with a ...

Pulse Biosciences closes enrollment in PRECISE-BTN Thyroid Nodule trial with first patient completing follow-up, positioning for primary dataset readout within ...

FDA aligns on RP-A501 Phase 2 trial design for Danon disease, approving a 12-patient pivotal population and 12-month endpoint structure.

Hinge Bio runs its Phase I trial on a single Medrio platform, consolidating EDC, ePRO, and RTSM to reduce setup time and site burden.

Mednet AI intake tool automates EHR-to-EDC data entry in clinical trials, reducing manual transcription and entry errors for research coordinators.

CRB-913 obesity drug achieved 5% weight loss in Phase 1b trial, signaling potential for a peripheral CB1 mechanism without central nervous system effects.

Professor Peter George, Pulmonologist at the Royal Brompton and Senior Medical Director at Brainomix, on why quantitative CT ...

Sionna advances SION-451 and SION-2222 into Phase 2a trial to test dual-corrector approach for Trikafta-resistant CF patients ...

MRI surveillance alone reduced cognitive failure risk by 40% versus MRI plus radiation in SCLC patients, per phase III ...

FDA held public hearing on psychedelic drug therapy with 80 speakers. Explore debates on safety, credentialing, and equitable ...